Lexeo Therapeutics (LXEO) Restructuring Costs (2024 - 2026)

Lexeo Therapeutics' Restructuring Costs history runs 3 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Restructuring Costs fell 62.52% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $29.1 million (down 10.78% YoY), while the FY2025 annual figure was $37.0 million, up 48.06% from the prior year.
• Restructuring Costs came in at $4.7 million for Q1 2026 at Lexeo Therapeutics, down from $9.3 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $12.6 million in Q1 2025 to a low of $2.9 million in Q3 2025.
• A 3-year average of $7.4 million and a median of $4.9 million in 2024 frame the typical range for Restructuring Costs.
• Across the five-year window, Restructuring Costs soared 209.04% in 2025 and tumbled 62.52% in 2026, its largest moves.
• Lexeo Therapeutics' Restructuring Costs stood at $11.8 million in 2024, then retreated by 21.02% to $9.3 million in 2025, then plunged by 49.47% to $4.7 million in 2026.
• According to Business Quant data, Restructuring Costs over the past three periods registered $4.7 million, $9.3 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison